New combo therapy aims to clear cloudy corneas by zapping and blocking blood vessels
NCT ID NCT07642960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a two-step treatment for corneal neovascularization, where abnormal blood vessels grow on the clear front part of the eye. First, doctors use a fine needle with heat to seal off the vessels, then inject a drug called bevacizumab to prevent regrowth. The trial will enroll 51 adults with stable corneal blood vessels and measure how much the vessels shrink over 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Bevacizumab (a drug that blocks blood vessel growth) and fine-needle diathermy (a procedure using heat to seal off abnormal blood vessels)
- What this could lead to
- If successful, this combination could offer a safe, effective way to reduce abnormal corneal blood vessels and potentially improve vision in affected patients.
- What could go wrong
- This is a small, early-phase trial with only 51 participants, so results may not apply to everyone. Risks include infection, scarring, or the blood vessels returning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 51 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age over 18 years. * Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination. * Corneal neovascularization is stable with no evidence of progression for at least 4 weeks. * Agreement to participate in the study and ability to comply with outpatient follow-up requirements Exclusion Criteria: * Pregnant or breastfeeding women. * History of hypersensitivity or allergy to bevacizumab or any component of the study medication. * Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease. * Active ocular infection or acute conjunctivitis at the time of enrollment. * Persistent corneal epithelial defect or delayed corneal epithelial healing. * History of ocular surgery within 3 months before study enrollment. * Corneal neovascularization associated with uncontrolled secondary glaucoma. * Inability or unwillingness to comply with study treatment or follow-up visits.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Corneal neovascularisation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
HoChiMinh City Eye Hospital
RECRUITINGHo Chi Minh City, Xuan Hoa, 72400, Vietnam